Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity.


Journal

Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 03 04 2020
accepted: 17 11 2020
entrez: 2 12 2020
pubmed: 3 12 2020
medline: 1 12 2021
Statut: epublish

Résumé

One ongoing concern about CRISPR-Cas9 genome editing is that unspecific guide RNA (gRNA) binding may induce off-target mutations. However, accurate prediction of CRISPR-Cas9 off-target activity is challenging. Here, we present SMRT-OTS and Nano-OTS, two novel, amplification-free, long-read sequencing protocols for detection of gRNA-driven digestion of genomic DNA by Cas9 in vitro. The methods are assessed using the human cell line HEK293, re-sequenced at 18x coverage using highly accurate HiFi SMRT reads. SMRT-OTS and Nano-OTS are first applied to three different gRNAs targeting HEK293 genomic DNA, resulting in a set of 55 high-confidence gRNA cleavage sites identified by both methods. Twenty-five of these sites are not reported by off-target prediction software, either because they contain four or more single nucleotide mismatches or insertion/deletion mismatches, as compared with the human reference. Additional experiments reveal that 85% of Cas9 cleavage sites are also found by other in vitro-based methods and that on- and off-target sites are detectable in gene bodies where short-reads fail to uniquely align. Even though SMRT-OTS and Nano-OTS identify several sites with previously validated off-target editing activity in cells, our own CRISPR-Cas9 editing experiments in human fibroblasts do not give rise to detectable off-target mutations at the in vitro-predicted sites. However, indel and structural variation events are enriched at the on-target sites. Amplification-free long-read sequencing reveals Cas9 cleavage sites in vitro that would have been difficult to predict using computational tools, including in dark genomic regions inaccessible by short-read sequencing.

Sections du résumé

BACKGROUND
One ongoing concern about CRISPR-Cas9 genome editing is that unspecific guide RNA (gRNA) binding may induce off-target mutations. However, accurate prediction of CRISPR-Cas9 off-target activity is challenging. Here, we present SMRT-OTS and Nano-OTS, two novel, amplification-free, long-read sequencing protocols for detection of gRNA-driven digestion of genomic DNA by Cas9 in vitro.
RESULTS
The methods are assessed using the human cell line HEK293, re-sequenced at 18x coverage using highly accurate HiFi SMRT reads. SMRT-OTS and Nano-OTS are first applied to three different gRNAs targeting HEK293 genomic DNA, resulting in a set of 55 high-confidence gRNA cleavage sites identified by both methods. Twenty-five of these sites are not reported by off-target prediction software, either because they contain four or more single nucleotide mismatches or insertion/deletion mismatches, as compared with the human reference. Additional experiments reveal that 85% of Cas9 cleavage sites are also found by other in vitro-based methods and that on- and off-target sites are detectable in gene bodies where short-reads fail to uniquely align. Even though SMRT-OTS and Nano-OTS identify several sites with previously validated off-target editing activity in cells, our own CRISPR-Cas9 editing experiments in human fibroblasts do not give rise to detectable off-target mutations at the in vitro-predicted sites. However, indel and structural variation events are enriched at the on-target sites.
CONCLUSIONS
Amplification-free long-read sequencing reveals Cas9 cleavage sites in vitro that would have been difficult to predict using computational tools, including in dark genomic regions inaccessible by short-read sequencing.

Identifiants

pubmed: 33261648
doi: 10.1186/s13059-020-02206-w
pii: 10.1186/s13059-020-02206-w
pmc: PMC7706270
doi:

Substances chimiques

RNA, Guide 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

290

Références

Nat Commun. 2016 Jun 30;7:12065
pubmed: 27356984
PLoS Genet. 2018 Jul 9;14(7):e1007503
pubmed: 29985941
Cell. 2019 Jan 24;176(3):663-675.e19
pubmed: 30661756
Mol Cell. 2018 Sep 6;71(5):816-824.e3
pubmed: 30078724
G3 (Bethesda). 2020 Feb 6;10(2):489-494
pubmed: 31822517
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Annu Rev Biophys. 2017 May 22;46:505-529
pubmed: 28375731
Am J Hum Genet. 2017 Aug 3;101(2):167-176
pubmed: 28777929
Nature. 2019 Dec;576(7785):149-157
pubmed: 31634902
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Cell. 2014 Jun 5;157(6):1262-1278
pubmed: 24906146
Nat Commun. 2019 Apr 16;10(1):1784
pubmed: 30992455
Nat Biotechnol. 2013 Sep;31(9):822-6
pubmed: 23792628
Nature. 2018 Sep;561(7723):416-419
pubmed: 30209390
Nat Commun. 2020 Jun 5;11(1):2861
pubmed: 32504042
Nat Biotechnol. 2020 Apr;38(4):433-438
pubmed: 32042167
Science. 2019 Apr 19;364(6437):286-289
pubmed: 31000663
Trends Biotechnol. 2019 Jan;37(1):72-85
pubmed: 30115375
Cell. 2018 May 31;173(6):1439-1453.e19
pubmed: 29856956
Genome Biol. 2016 Jul 05;17(1):148
pubmed: 27380939
Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
Cell Death Dis. 2018 Oct 27;9(11):1099
pubmed: 30368519
Nat Rev Drug Discov. 2017 Feb;16(2):89-100
pubmed: 28008168
Nat Protoc. 2018 Nov;13(11):2615-2642
pubmed: 30341435
Genes (Basel). 2018 Oct 09;9(10):
pubmed: 30304863
J Mol Biol. 2019 Jan 4;431(1):88-101
pubmed: 29885329
Nat Commun. 2019 Dec 4;10(1):5525
pubmed: 31797925
Bioinformatics. 2014 May 15;30(10):1473-5
pubmed: 24463181
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
Nat Med. 2017 Sep;23(9):1095-1101
pubmed: 28759051
Genome Biol. 2019 May 20;20(1):97
pubmed: 31104630
Bioinformatics. 2019 Sep 1;35(17):2907-2915
pubmed: 30668829
Nature. 2020 Sep;585(7823):79-84
pubmed: 32663838
Nat Biotechnol. 2019 Oct;37(10):1155-1162
pubmed: 31406327
Nat Methods. 2017 Jun;14(6):607-614
pubmed: 28459458
Nat Biotechnol. 2020 Nov;38(11):1317-1327
pubmed: 32541958
Eur J Hum Genet. 2017 Nov;25(11):1253-1260
pubmed: 28832569
Nat Biotechnol. 2013 Mar;31(3):230-2
pubmed: 23360966
Genome Res. 2016 Mar;26(3):406-15
pubmed: 26786045
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nat Med. 2019 May;25(5):776-783
pubmed: 30911135
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Nat Biotechnol. 2013 Sep;31(9):833-8
pubmed: 23907171
Nucleic Acids Res. 2019 Jul 2;47(W1):W171-W174
pubmed: 31106371
Nat Methods. 2015 Mar;12(3):237-43, 1 p following 243
pubmed: 25664545
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Hum Mutat. 2018 Sep;39(9):1262-1272
pubmed: 29932473
Nat Methods. 2017 Jun;14(6):600-606
pubmed: 28459459
Elife. 2013 Jan 29;2:e00471
pubmed: 23386978
Cell Biol Toxicol. 2020 Feb;36(1):5-9
pubmed: 31734746

Auteurs

Ida Höijer (I)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. ida.hoijer@igp.uu.se.

Josefin Johansson (J)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Sanna Gudmundsson (S)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.

Chen-Shan Chin (CS)

Foundation for Biological Data Science, Belmont, CA, USA.

Ignas Bunikis (I)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Susana Häggqvist (S)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Anastasia Emmanouilidou (A)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
The Beijer laboratory and Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Maria Wilbe (M)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Marcel den Hoed (M)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
The Beijer laboratory and Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Marie-Louise Bondeson (ML)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Lars Feuk (L)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Ulf Gyllensten (U)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Adam Ameur (A)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. adam.ameur@igp.uu.se.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. adam.ameur@igp.uu.se.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH